Promotion A. Strandmoe

The circulating immune profile of pemphigus: Insights into B cells, rituximab response, and relapse

Pemphigus vulgaris is a rare autoimmune disease in which the immune system attacks the body and causes blisters on the skin and inside the mouth. This happens because the body mistakenly targets proteins called desmogleins (DSG) that help keep skin cells attached to each other. Although rituximab has greatly improved treatment outcomes and is now an important therapy for pemphigus, many patients still relapse after treatment. 

Pemphigus is often described as a disease caused by harmful B cells, the immune cells that produce antibodies. However, the immune system is much more complex and also includes many other cells and signalling proteins that may contribute to disease activity and relapse. This thesis by Anne-Lise Strandmoe aimed to better understand the circulating immune system in pemphigus, with particular focus on B cells, the effects of rituximab treatment, and mechanisms related to relapse. 

The findings of this thesis show that pemphigus is not only a B-cell disease but involves broader immune changes. Rituximab strongly affects the circulating B-cell system and improves disease control, yet relapse remains common. The findings suggest that better monitoring of the immune system, more complete removal of harmful B cells, and more individualized treatment strategies may help improve long-term outcomes for patients with pemphigus.

Find the full thesis here: The circulating immune profile of pemphigus: Insights into B cells, rituximab response, and relapse